Buy AbbVie stock | $ABBV Share Price

AbbVie falls after mixed Q4 results, with Humira sales down 26%, oncology and aesthetics revenues below forecasts, overshadowing an 18% immunology sales gain.

18 hours ago·Lightyear AI

14:30

16:10

17:45

19:25

21:00

About AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Ticker

$ABBV

Sector

Health

Primary listing

NYSE

Employees

55,000

Headquarters

North Chicago, United States

Website

www.abbvie.com

AbbVie Metrics

BasicAdvanced

$384B

92.00

$2.36

$6.56

3.02%

What the Analysts think about AbbVie

Analyst ratings (Buy, Hold, Sell) for AbbVie stock.

Bulls say / Bears say

AbbVie secured a settlement that blocks generic competition for Rinvoq until April 2037, backing projections of peak global sales close to $19 billion and combined Skyrizi and Rinvoq revenues topping $31 billion by 2027.

After reporting Q3 2025 results, AbbVie raised its full‐year adjusted EPS forecast to $10.61–$10.65 following 9.1% year‐over‐year revenue growth to $15.78 billion, with strong contributions from immunology and neuroscience.

AbbVie announced a 5.5% rise in its quarterly dividend for 2026, its 14th consecutive annual increase, highlighting continued robust free cash flow.

Sales of Humira declined 55.4% year-over-year to $993 million in Q3 2025, as biosimilar competition accelerated and significantly reduced its legacy immunology business.

The aesthetics segment posted a 3.7% decrease in net revenues to $1.193 billion in Q3 2025; Botox Cosmetic fell 4.9% and Juvederm dropped 2.2%, showing pressure from softer consumer spending.

Oncology net revenues were nearly flat, inching down 0.3% year-over-year to $1.682 billion in Q3 2025, pointing to stagnation in AbbVie’s oncology franchise.

Data summarised monthly by Lightyear AI. Last updated on 31 Jan 2026.

AbbVie Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

AbbVie Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ABBV

Capital at risk

Market closed

Upcoming events

FAQs

What’s the current market cap for AbbVie stock?

AbbVie (ABBV) has a market cap of $384B as of February 05, 2026.

What is the P/E ratio for AbbVie stock?

The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 92 as of February 05, 2026.

Does AbbVie stock pay dividends?

Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of February 05, 2026, the dividend rate is $6.56 and the yield is 3.02%. AbbVie has a payout ratio of 0% on a trailing twelve-month basis.

When is the next AbbVie dividend payment date?

The next AbbVie (ABBV) dividend payment is scheduled for February 17, 2026.

What is the beta indicator for AbbVie?

AbbVie (ABBV) does not currently have a Beta indicator.